The cost of developing drugs is rising at an unsustainable pace, new company formation in the biotech sector has dwindled, and healthcare costs continue to rise. We must craft policies that provide the proper incentives for new technology while making sure that we are getting more value for programs like Medicare.

Economist Martin Gaynor will present his recent analysis of NHS reforms, and UnitedHealth Group's Simon Stevens will discuss whether and how a greater dose of competition might improve hospital care for American patients.

Here is another good news/bad news column about the 112th Congress.

A new approach to reform is needed, one that levels with the American people about what is possible and what is necessary. AEI scholars Joseph Antos and Thomas P. Miller have written a realistic, market-based proposal.

H.R. 4489 focuses on a specific market: prescription drug coverage for federal employees; the legislation would impose a wide variety of restrictions, controls, and mandates.

Buying drugs online may not be as dangerous as you think.